Wall Street brokerages forecast that Healthequity Inc (NASDAQ:HQY) will post earnings per share of $0.25 for the current quarter, according to Zacks. Eight analysts have made estimates for Healthequity’s earnings. The highest EPS estimate is $0.28 and the lowest is $0.23. Healthequity posted earnings per share of $0.17 in the same quarter last year, which suggests a positive year-over-year growth rate of 47.1%. The company is scheduled to announce its next quarterly earnings results on Tuesday, December 4th.

On average, analysts expect that Healthequity will report full-year earnings of $1.10 per share for the current fiscal year, with EPS estimates ranging from $1.03 to $1.20. For the next financial year, analysts expect that the firm will report earnings of $1.36 per share, with EPS estimates ranging from $1.25 to $1.59. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Healthequity.

Healthequity (NASDAQ:HQY) last issued its earnings results on Tuesday, September 4th. The company reported $0.34 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.22 by $0.12. The company had revenue of $71.10 million during the quarter, compared to analyst estimates of $69.84 million. Healthequity had a return on equity of 12.58% and a net margin of 23.81%. The firm’s quarterly revenue was up 25.0% on a year-over-year basis. During the same quarter last year, the business posted $0.27 EPS.

A number of brokerages recently issued reports on HQY. KeyCorp raised their target price on Healthequity from $82.00 to $90.00 and gave the stock a “buy” rating in a research note on Thursday, July 19th. SunTrust Banks raised their target price on Healthequity to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, September 5th. Zacks Investment Research upgraded Healthequity from a “sell” rating to a “hold” rating in a research note on Friday, July 20th. Cantor Fitzgerald reiterated a “hold” rating and set a $68.00 price objective (up previously from $65.00) on shares of Healthequity in a research note on Monday, June 4th. Finally, Raymond James lifted their price objective on Healthequity from $85.00 to $105.00 and gave the company an “outperform” rating in a research note on Monday, September 10th. Four equities research analysts have rated the stock with a hold rating, nine have given a buy rating and two have given a strong buy rating to the company’s stock. Healthequity has an average rating of “Buy” and a consensus target price of $93.08.

In other news, VP Darcy G. Mott sold 4,000 shares of the firm’s stock in a transaction dated Monday, August 20th. The stock was sold at an average price of $86.37, for a total transaction of $345,480.00. Following the sale, the vice president now directly owns 99,200 shares in the company, valued at approximately $8,567,904. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank Medici sold 15,596 shares of the firm’s stock in a transaction dated Tuesday, July 10th. The shares were sold at an average price of $80.15, for a total value of $1,250,019.40. Following the sale, the director now owns 26,341 shares in the company, valued at $2,111,231.15. The disclosure for this sale can be found here. Insiders have sold a total of 41,500 shares of company stock valued at $3,312,481 in the last quarter. Company insiders own 4.00% of the company’s stock.

Several large investors have recently bought and sold shares of HQY. Citigroup Inc. grew its position in shares of Healthequity by 414.4% during the 1st quarter. Citigroup Inc. now owns 2,639 shares of the company’s stock valued at $160,000 after acquiring an additional 2,126 shares during the period. Advisors Asset Management Inc. grew its position in shares of Healthequity by 5,212.2% during the 2nd quarter. Advisors Asset Management Inc. now owns 72,086 shares of the company’s stock valued at $160,000 after acquiring an additional 70,729 shares during the period. Rockefeller Capital Management L.P. acquired a new stake in shares of Healthequity during the 2nd quarter valued at about $179,000. Cim LLC acquired a new stake in shares of Healthequity during the 2nd quarter valued at about $204,000. Finally, S&CO Inc. acquired a new stake in shares of Healthequity during the 2nd quarter valued at about $204,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

HQY stock traded up $0.39 during midday trading on Friday, reaching $94.70. The stock had a trading volume of 12,311,264 shares, compared to its average volume of 518,753. The firm has a market capitalization of $5.86 billion, a price-to-earnings ratio of 175.37, a price-to-earnings-growth ratio of 3.32 and a beta of 1.47. Healthequity has a 52-week low of $42.92 and a 52-week high of $99.99.

About Healthequity

HealthEquity, Inc provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. The company offers healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.

Featured Article: NASDAQ

Get a free copy of the Zacks research report on Healthequity (HQY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Healthequity (NASDAQ:HQY)

Receive News & Ratings for Healthequity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthequity and related companies with MarketBeat.com's FREE daily email newsletter.